Medicine: Outside the fold

Journal name:
Nature
Volume:
508,
Pages:
180–181
Date published:
DOI:
doi:10.1038/508180a
Published online

Giovanna Mallucci assesses the autobiography of Stanley Prusiner, the discoverer of prions.

Madness and Memory: The Discovery of Prions — A New Biological Principle of Disease

Stanley B. Prusiner Yale University Press: 2014. ISBN: 9780300191141

Buy this book: US UK Japan

In his autobiographical book, Madness and Memory, Stanley Prusiner charts his journey to winning the 1997 Nobel Prize for Physiology or Medicine, 30 years after his first laboratory posting as a fourth-year medical student — in Sweden, coincidentally. As the subtitle states, the story hinges on Prusiner's discovery of prions, “a new biological principle of disease”. It is a remarkable tale: for the scientific discovery at its centre; for its recording of the extraordinary resistance the idea engendered; and for the sheer unfettered animosity, both personal and professional, directed at him throughout from scientists and the media.

Illustration by Martin O'Neill; Stanley Prusiner photo: Russ Fischella

Prusiner introduces us early on to how, in 1972, his imagination was caught by the then-unknown infectious agent causing scrapie, a degenerative brain disease of sheep. Then, in the first year of his neurology residency, he was caring for a patient with Creutzfeldt–Jakob disease (CJD), a scrapie-like neurodegenerative disorder we now know to be a human prion disease. What follows is a chronicle of his voyage to isolate and characterize the scrapie agent during the 1970s, up to his demonstration in 1981 that the agent is a protein, devoid of nucleic acid and capable of replicating itself and transmitting disease.

Details of scientific milestones are interwoven with Prusiner's accounts of personal interactions with colleagues at each stage; descriptions of dramatic epidemics of prion diseases across the globe punctuate the story. These include the phenomenon of kuru, a scrapie-like disease first described by Carleton Gajdusek in the 1950s, found among the Fore people of Papua New Guinea who practised ritualistic cannibalism; and the late 1980s disaster of bovine spongiform encephalopathy (BSE) in UK cattle, which spread to humans as variant CJD. Altogether, the story highlights the extraordinary scientific, medical and political climate of this period. There are struggles for funding, Prusiner's battle for tenure at the University of California, San Francisco, and the fight for scientific recognition at every stage of his career.

“Prusiner's proof engendered disbelief, anger, denial and widespread refusal.”

The idea of an infectious protein was first mooted in London in the 1960s by the mathematician John Stanley Griffith, and separately by the radiation biologist Tikvah Alper. Both published papers in Nature in 1967: 'Self-replication and scrapie' (J. S. Griffith Nature 215, 10431044; 1967) and 'Does the agent of scrapie replicate without nucleic acid?' (T. Alper et al. Nature 214, 764766; 1967). But it was Prusiner who pursued the idea and Prusiner who proved it, with a determination that earned him both admiration (including the Lasker and Nobel prizes) and blind hostility.

Prusiner's proof of the revolutionary concept that infectivity in these disorders proceeds without nucleic acids, and his coinage of the term prion — for proteinaceous infectious particle (S. B. Prusiner Science 216, 136144; 1982) — engendered disbelief, anger, denial and widespread refusal from a hostile scientific community, including many virologists. This antipathy persisted right up to the awarding of his Nobel prize. A 1997 article in The New Yorker asked, “But what if he's wrong?”; one in Slate was entitled 'Nobel Gas: Sure, Stanley Prusiner deserves a prize — for his persistence, not for his prions.' That Prusiner withstood these public attacks in his moments of greatest recognition is laudable, and gives some insight into his tenacity.

Scientifically, the story progresses from descriptions of labs full of antediluvian centrifuges with custom-built safety cabins around them (for isolation of the infectious agent from infected hamster brains) to the elegant transgenic mouse experiments of the prion era and the concept of misfolded endogenous proteins associated with disease. The story is testament to the staggering intellect and courage involved in one of the most exciting discoveries since the DNA double helix.

But for all its drama, this extraordinary scientific story is not always an easy read. Prusiner's description of scientific rivalries inevitably reflects his version of events. His relationship with Gajdusek, whom he had visited in Papua New Guinea, ends bitterly, with arguments over Gajdusek's claims to the prion concept. Prusiner's collaboration with Swiss molecular biologist Charles Weissmann began brilliantly but became strained. Weissmann discovered that prion protein is encoded by a host gene — a finding as important to the prion story as the infectious protein itself. Prusiner's account of that collaboration's end, complete with transcripts of letters he sent to Weissmann, is an uncomfortable read. 'Scientific Interludes' explaining concepts and technicalities in some detail are interspersed through the text. There are other inserts: technical, graphical and bibliographical. Many are fascinating, but they tend to interrupt the flow of the compelling narrative.

The concluding chapter's meditation on the prion concept in widespread neurodegenerative disorders such as Alzheimer's is highly topical, albeit inordinately specialized in its detail. The book ends with an exhortation to the US government to fund research into cures for neurodegenerative disorders, diseases that Prusiner claims have “been ignored”. He will be glad that last December's G8 Dementia Summit means that the world is heeding his call and taking this issue seriously at last.

Author information

Affiliations

  1. Giovanna Mallucci is professor of neuroscience at the MRC Toxicology Unit, Leicester, UK, and honorary consultant neurologist at Addenbrooke's Hospital, Cambridge, UK. She works on neurodegeneration, focusing on prion diseases.

Corresponding author

Correspondence to:

Author details

Additional data